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Introduction
An appropriate supply of  extracellular L-arginine, a semiessential amino acid that has long been associ-
ated with the amelioration of  immune responses (1–5), is essential for T cell function (6). Both human 
and mouse T cells require sufficient extracellular arginine for expression of  the T cell receptor–associated 
(TCR-associated) CD3ζ chain, cell cycle progression and proliferation, cytokine production, and memory 
differentiation (7–9). Thus, depletion of  extracellular arginine is one of  the mechanisms that tumors exploit 
to create an immunosuppressive microenvironment restraining antitumor T cell responses.
In addition to being an essential building block for protein synthesis, arginine is a substrate for 
several enzymes, including nitric oxide synthases (NOS) and arginases, the latter converting arginine 
into urea and ornithine. Mammals have 2 arginases, Arg1 and Arg2, which differ in their intracellular 
localization, expression patterns, and biological significance. Arg1 is the isoform for which the biolog-
ical roles have been most well defined. It is a cytosolic enzyme best known for its prominent role in the 
hepatic urea cycle, and it is critical for ammonia detoxification (10). However, in many cancer types, 
elevated Arg1 activity from tumor cells or tumor-associated myeloid cells participates in the establish-
ment of  an arginine-poor immunosuppressive microenvironment.
Arg2 is a mitochondrial enzyme that has a widespread pattern of  expression, present in diverse cell 
types (10, 11). Arg2 is attributed to correspond to the ancestral gene from which Arg1 emerged by dupli-
cation during animal terrestrial adaptation (12). There is some evidence that Arg2 can, like Arg1, exert 
immunosuppressive effects by inducing extracellular arginine depletion. For instance, we previously 
demonstrated that the miR155 represses Arg2 expression in DCs to ultimately establish an arginine-rich 
microenvironment, which is permissive for T cell proliferation (13). Similarly, Arg2 expression by fetal 
As sufficient extracellular arginine is crucial for T cell function, depletion of extracellular arginine 
by elevated arginase 1 (Arg1) activity has emerged as a hallmark immunosuppressive mechanism. 
However, the potential cell-autonomous roles of arginases in T cells have remained unexplored. Here, 
we show that the arginase isoform expressed by T cells, the mitochondrial Arg2, is a cell-intrinsic 
regulator of CD8+ T cell activity. Both germline Arg2 deletion and adoptive transfer of Arg2–/– CD8+ 
T cells significantly reduced tumor growth in preclinical cancer models by enhancing CD8+ T cell 
activation, effector function, and persistence. Transcriptomic, proteomic, and high-dimensional 
flow cytometry characterization revealed a CD8+ T cell–intrinsic role of Arg2 in modulating T cell 
activation, antitumor cytoxicity, and memory formation, independently of extracellular arginine 
availability. Furthermore, specific deletion of Arg2 in CD8+ T cells strongly synergized with PD-1 
blockade for the control of tumor growth and animal survival. These observations, coupled with the 
finding that pharmacologic arginase inhibition accelerates activation of ex vivo human T cells, unveil 
Arg2 as a potentially new therapeutic target for T cell–based cancer immunotherapies.
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DCs and neonatal erythroid cells was reported to quench deleterious T cell responses (14, 15) during 
pregnancy and in newborns.
In contrast to the aforementioned mechanisms, invoking immunosuppressive effects of  extracellular 
arginine depletion by arginases, recent evidence has also suggested that Arg2 could have direct cell-au-
tonomous roles in T cells themselves. Pharmacological arginase inhibition was found to increase in vitro 
survival of  human T cells, which express only Arg2 (16). Additionally, enhanced survival was also observed 
for Arg2-deficient mouse T cells (16). Because these experiments were performed under excess arginine con-
ditions, and therefore independent of  extracellular arginine availability, they argue for a cell-autonomous 
role of  Arg2. The mitochondrial localization of  Arg2 raises the intriguing possibility that such observations 
could be due to a direct effect of  Arg2 on T cell metabolism. However, T cell autonomous roles of  Arg2 
have not been defined, to date.
Here, we investigated the functional repercussions of  genetic ablation of  Arg2 in mouse CD8+ 
T cells using preclinical cancer models as in vivo readouts for CD8+ T cell responses. Intriguingly, 
Arg2-deficient CD8+ T cells were markedly superior at controlling tumor growth and in a manner exhib-
iting strong synergy with PD-1 blockade. In vivo and in vitro experiments demonstrated that the poten-
tiated antitumor activity of  Arg2-deficient CD8+ T cells could be attributed to accelerated activation 
kinetics, the acquisition of  more robust effector functions, increased persistence of  the T cell response, 
and enhanced memory T cell formation. These alterations were due to cell-autonomous mechanisms, 
as they were observed in an otherwise Arg2-proficient background in vivo or independently of  extracel-
lular arginine availability in vitro. Notably, pharmacological arginase inhibition in human CD8+ T cells 
recapitulated the enhanced activation phenotype observed in mouse Arg2–/– CD8+ T cells, suggesting a 
conserved regulatory function of  Arg2 in T cells. Taken together, our results demonstrate a potentially 
novel cell-autonomous role of  Arg2 for the modulation of  T cell function. Moreover, they pave the way 
for the development of  novel strategies to enhance the efficacy and persistence of  T cell–based cancer 
immunotherapies by targeting Arg2 expression or function in T cells.
Results
Arg2–/– mice exhibit enhanced antitumor responses. To investigate the in vivo relevance of  Arg2 in antitumor 
immune responses, Arg2–/– mice (17) were injected s.c. with syngeneic B16 melanoma or MC38 colorec-
tal carcinoma cells expressing OVA as surrogate tumor antigen. Growth of  B16-OVA and MC38-OVA 
tumors was significantly reduced in Arg2–/– males and females (Figure 1, A and C, and Supplemental 
Figure 1, A and B; supplemental material available online with this article; https://doi.org/10.1172/jci.
insight.132975DS1), yielding smaller tumors 12 or 14 days after tumor injection, respectively (Figure 1, B 
and D). Up to 60% of  male Arg2–/– mice remained tumor free (Supplemental Figure 1B). Major populations 
of  CD4+ and CD8+ tumor-infiltrating lymphocytes (TILs) present within MC38-OVA tumors were quanti-
fied by flow cytometry. Tumors in Arg2–/– mice presented significantly elevated frequencies of  CD8+ TILs, 
whereas frequencies of  total CD4+ TILs remained unchanged (Figure 1, E and F). However, the frequen-
cies of  CD4+FoxP3+ Tregs were reduced (Figure 1G) in tumors of  Arg2–/– hosts; consequently, the CD8+/
Treg ratio was 3-fold greater in such tumors (Figure 1H). Moreover, ex vivo restimulation demonstrated 
that IFN-γ expression in CD4+ TILs was superior in Arg2–/– hosts (Supplemental Figure 1C), and a simi-
lar tendency was also observed for CD8+ TILs. The latter cells also showed reduced CTLA-4 expression 
(Figure 1, I and J). All mentioned differences were restricted to T cells in the effector site, as they were not 
observed for T cells in tumor-draining lymph nodes (TdLNs).
As arginine is an essential nutrient for T cells, we measured arginine levels by high-performance liquid 
chromatography–mass spectrometry (HPLC-MS) in naive and tumor-bearing mice. As described previously 
(17), naive Arg2–/– mice presented approximately 1.5-fold higher serum arginine concentrations (Figure 1K), 
indicating a major contribution of Arg2 to the homeostasis of circulating arginine. Arg2–/– mice also presented 
higher concentrations of arginine in secondary lymphoid organs (Figure 1L), suggesting a considerable level of  
Arg2 activity in these tissues. Furthermore, more elevated arginine concentrations were detected in B16-OVA 
tumors growing in Arg2–/– hosts (Figure 1M), advocating for a more favorable tumor microenvironment (TME) 
in these hosts with increased arginine availability.
Collectively, these results suggest that systemic Arg2 deficiency leads to reduced tumor growth as a 
consequence of  increased infiltration by CD8+ TILs, which could function more efficiently in a more hospi-
table TME, with higher arginine availability and reduced immunosuppressive pressure from Tregs.
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To exclude the possibility that enhanced tumor control in Arg2–/– mice might be secondary to major 
genotype-related developmental or anatomical defects, we also performed comprehensive histopatho-
logical and flow cytometry analyses. No overt morphological or histological abnormalities were evi-
dent in any organs in either young or aged Arg2–/– mice (Supplemental Table 1). Young Arg2–/– males 
presented a slight increase in heart weight, and both young and aged Arg2–/– males and females exhib-
ited a moderate increase in spleen weight (Supplemental Figure 1, D and E), although no prevalent 
pathological conditions were associated with these increases in organ weight (Supplemental Table 1, A 
and B). Additional flow cytometry experiments also demonstrated that frequencies of  major DC and 
Figure 1. Deletion of Arg2 reduces tumor growth and increases arginine availability. (A–D) Analysis of tumor growth (A) for B16-OVA (n = 10) and 
(C) for MC38-OVA (n = 13) and tumor weight at (B) day 12 or (D) day 14 tumors in WT or Arg2–/– hosts. (E–I) T cell frequencies in tumor-draining 
lymph nodes (TdLN) and tumors in 9-day MC38-OVA tumor-bearing WT and Arg2–/– mice: (E) CD8+ T cells; (F) CD4+ T cells; (G) FoxP3+ Tregs; (H) CD8+/
FoxP3+ T cell ratio; (I) IFN-γ+CD8+ T cells. (J) Analysis of CTLA-4 expression by CD8+ T cells. (K–M) HPLC-MS quantification of arginine in (K) serum, (L) 
secondary lymphoid organs (SLO), and (M) B16-OVA tumors 12 days after tumor implantation in WT or Arg2–/– mice. Results were pooled from 2 or 3 
independent experiments (A, C, E–M) or are representative of 3 independent experiments (B and D). Data is represented as mean ± SEM throughout. 
*P < 0.05, **P < 0.01, and ****P < 0.0001 (A and C: 2-way ANOVA) (B, D–M: 2-tailed Student’s t test).
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Figure 2. Arg2–/– mice control tumor growth more efficiently via enhanced cytotoxic CD8+ T cell function. (A) Tumor growth and (B) mouse survival in 
MC38-OVA tumor-bearing WT or Arg2–/– mice treated with CD8+ T cell–depleting (αCD8α) or isotype control (IgG2a) antibodies (n = 18–21). (C) Tumor growth 
and (D) mouse survival were analyzed in MC38-OVA tumor-bearing WT or Arg2–/– mice treated with CD4+ T cell depleting (αCD4) or isotype control (IgG2b) 
antibodies (n = 11–12). (A–D) Mice received 4 mg/kg doses of depleting or control antibody at days –3, –1, 1, 4, 8, 11, 15, and 18 relative to tumor injection. (E) 
WT and Arg2–/– mice that had been immunized 6 days earlier with OVA257–264 and CpG-B were implanted with CTV
lo control or CTVhi OVA257–264–loaded synge-
neic splenocytes, and target cell clearance was evaluated in the spleens after 24 hours. (F and G) CTVlo control or CTVhi OVA257–264–loaded syngeneic spleno-
cytes were transferred into 11-day (F) B16-OVA or (G) MC38-OVA tumor-bearing WT or Arg2–/– mice, and target cell clearance was evaluated after 24 hours 
in the tumor-draining lymph nodes (TdLNs) and contralateral nondraining lymph nodes (ndLNs). Target cell clearance in the TdLNs is expressed as killing 
ratio relative to the control cells and was normalized relative to the killing ratio in the ndLNs. (H) Naive WT or Arg2–/– mice received CTVlo control or CTVhi 
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lymphocyte populations were not altered significantly in the spleens or lymph nodes (LNs) of  Arg2–/– 
mice (Supplemental Figure 1F).
Enhanced antitumor CD8+ T cell responses in Arg2–/– mice. We next performed antibody-mediated depletion 
experiments to assess the respective roles of CD4+ and CD8+ T cells in the control of tumor growth in WT and 
Arg2–/– mice. Depletion of CD8+ T cells in Arg2–/– mice impaired their capacity to control tumor growth; tumors 
grew more aggressively than in isotype-injected Arg2–/– controls and reduced mouse survival (Figure 2, A and B). 
However, this loss of tumor control did not fully recapitulate what was observed upon depletion of CD8+ T cells 
in WT hosts, suggesting that additional mechanisms are at play in Arg2–/– hosts. One possible explanation is that 
residual CD8+ T cells present in the depleted mice (Supplemental Figure 2A) are more effective at controlling 
tumor growth in the Arg2–/– background because they encounter fewer tumor-infiltrating Tregs (Figure 1H) or 
because they encounter a more arginine-rich TME (Figure 1M). Depletion of CD4+ T cells markedly improved 
tumor control and mouse survival in Arg2–/– mice but had little effect in WT mice (Figure 2, C and D). These 
results indicate that CD8+ T cells confer enhanced protection against tumor growth in both WT and Arg2–/– 
hosts, whereas CD4+ T cells exert an immunosuppressive effect that is more evident in Arg2–/– hosts.
To confirm that cytotoxic antitumor CD8+ T cell responses are enhanced in Arg2–/– mice, we performed 
in vivo killing assays. In these experiments, mice that had been preimmunized 6 days earlier with MHC 
class I–restricted OVA257–264 peptide were inoculated with syngeneic OVA257–264–loaded and unloaded sple-
nocytes. Twenty-four hours later, we assessed the relative clearance of  the 2 splenocyte populations in host 
spleens by flow cytometry. Arg2–/– hosts showed significantly increased clearance of  OVA257–264–loaded sple-
nocytes (Figure 2E). A similar approach was used to assess CD8+ T cell cytotoxicity, in a tumor context, 
in TdLNs of  B16-OVA or MC38-OVA tumor-bearing mice. In both tumor models Arg2–/– hosts showed 
superior clearance of  OVA257–264–loaded splenocytes (Figure 2, F and G). These results demonstrate that 
Arg2–/– mice indeed exhibit enhanced CD8+ T cell cytotoxicity.
To determine whether NK cell cytotoxic activity might also be affected by Arg2 deficiency, congenic B2m–/– 
splenocytes were transferred into naive WT or Arg2–/– mice. In this case, the MHC class I–deficient splenocytes 
were cleared equally in WT and Arg2–/– hosts (Figure 2H). Thus, in contrast to CD8+ T cell responses, NK cell 
cytotoxicity is not significantly altered in Arg2–/– mice and cannot account for enhanced tumor control observed 
in CD8+ T cell–depleted Arg2–/– mice relative to CD8+ T cell–depleted WT mice (Figure 2A).
To investigate whether Arg2 deficiency in radioresistant or BM-derived cells is responsible for enhanced 
antitumor responses in Arg2–/– mice, we next assessed MC38-OVA tumor growth in BM chimeras. Both WT 
and Arg2–/– hosts reconstituted with Arg2–/– BM exhibited a strong reduction in tumor growth compared with 
WT or Arg2–/– hosts reconstituted with WT BM (Figure 2I). Consequently, tumor-bearing chimeras reconstitut-
ed with Arg2–/– BM exhibited improved tumor clearance rates and prolonged survival (Figure 2, J and K), firm-
ly suggesting that enhanced tumor control in Arg2–/– mice is therefore mainly due to the loss of Arg2 expression 
in cells of hematopoietic origin. Additionally, a small but significant difference between Arg2–/–-reconstitued 
WT and Arg2–/– suggests a minor contribution from radioresistant cells for tumor control in Arg2–/– hosts.
Arg2 deficiency improves T cell function in vitro. As mentioned above, we previously reported that inhibition 
of Arg2 mRNA expression by miR155 is required for optimal DC function (13). To determine whether this 
control of Arg2 expression also takes place in T cells, we quantified Arg2 mRNA by quantitative PCR (qPCR) 
in WT and miR155-deficient T cells at different times after αCD3ε/αCD28 activation (Figure 2, L–O, and Sup-
plemental Figure 1, G and H). The results demonstrated that induction of miR155 expression (Figure 2, L and 
M) indeed suppresses an early (prior to 12 hours) and transient increase in Arg2 mRNA abundance in CD4+ 
and CD8+ T cells (Figure 2, N and O). Instead, Arg1 mRNA was barely detectable in activated T cells and not 
subject to regulation by miR155 (Supplemental Figure 1, G and H). These results suggest that suppression of  
Arg2 expression in activated T cells could also be required for their optimal function.
To investigate the functional impact of suppressing Arg2 expression in T cells, we searched for phenotypic 
changes between WT and Arg2–/– OT-I CD8+ T cells activated in vitro with anti-CD3ε and anti-CD28 antibodies. 
β2m–/– syngeneic splenocytes, and target cell clearance was evaluated in spleen after 24 hours. Target cell clearance is expressed as killing ratio relative to 
the control cells. (I) Tumor growth, (J) tumor clearance rates at day 40, and (K) mouse survival were assessed in the indicated 4 groups of BM chimeric mice 
(n = 11–12). (L–O) miR155 (bic RNA) or Arg2 mRNA were quantified by real-time PCR over a 48-hour time course in ex vivo WT or miR155–/– CD4+ (L and N) or 
CD8+ (M and O) T cells activated with αCD3ε and αCD28 antibodies (n = 6). (A–O) Results were pooled from 2 or 3 independent experiments. Data is repre-
sented as mean ± SEM throughout. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 (A, C, I, L–O: 2-way ANOVA) (E–G: 2-tailed Student’s t test) (B, 
D, K: log-rank Mantel-Cox test) (J: Fisher’s exact test).
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Flow cytometry experiments indicated that Arg2–/– cells exhibited faster and stronger activation dynamics: shed-
ding of CD62L occurred significantly faster in Arg2–/– cells, becoming already evident within the first hour of acti-
vation (Figure 3, A and B); upregulation of CD69 was higher in Arg2–/– cells and remained more robustly higher, 
even after arginine concentrations in the culture medium were reduced to limiting levels (Figure 3C). In contrast, 
CellTrace Violet (CTV) dilution assays revealed that the proliferative capacity of Arg2–/– cells was not affected at 
any of the tested arginine concentrations (Supplemental Figure 3, A and B).
Notably, pharmacologic inhibition of  ARG2 also increased the activation dynamics of  ex vivo–cul-
tured human T cells. Thus, 24 hours after CD3ε and CD28 ligation, both CD4+ and CD8+ human T cells 
treated with panarginase inhibitors presented higher frequencies of  CD69+ cells and CD62Llo cells (Supple-
mental Figure 3, C–F). In parallel, ELISA and in vitro restimulation experiments revealed that activated 
Arg2–/– cells produce higher amounts of  IFN-γ (Figure 3, D and E). Additionally, qPCR analysis demon-
strated that activated Arg2–/– cells exhibited stronger induction of  Ifng and Il2 mRNAs (Figure 3, F and 
G), while the induction of  mRNAs encoding key enzymes involved in nitric oxide production (Nos2) and 
glucose metabolism (Gapdh) remained unaffected (Figure 3, H and I).
To obtain a more in-depth description of  the altered properties of  Arg2–/– CD8+ T cells, we performed 
a time-course transcriptome analysis by RNA sequencing (RNA-seq) of  in vitro–activated WT and Arg2–/– 
OT-I cells. An unbiased strategy based on a comprehensive gene set enrichment analysis (GSEA) was used 
to identify key pathways that are differentially regulated in Arg2–/– T cells (Figure 4A and Supplemental 
Figure 4). Several functions were significantly upregulated at most time points in Arg2–/– cells relative to 
WT cells, including “cytotoxicity,” “IFN-γ signalling,” “cytokines and inflammatory response,” and “IL-2 
signalling” categories (Figure 4A and Supplemental Figure 4). Other functions, such as “biosynthesis of  
amino acids,” were downregulated at early time points but equalized at later time points. Many key genes 
within the upregulated categories were expressed more strongly in Arg2–/– cells after 2, 6, and 12 hours of  
activation, although some were already elevated prior to activation (0 hours), suggesting that Arg2–/– cells 
could be primed to respond more strongly (Figure 4, B–F).
Notable cytotoxicity genes upregulated in Arg2–/– cells were those encoding granzymes, perforin, and Fas 
ligand. Key cytokine and cytokine receptor genes upregulated in Arg2–/– cells included those for IFN-γ (Ifng) 
and one of its receptor subunits (Ifngr1), IL-2 (Il2) and its 3 receptor subunits (Il2ra, Il2rb, Il2rg), GM-CSF (Csf2), 
IL-3 (Il3), and TNF-α (Tnf). Three genes (Eomes, Tbx21, Runx2) encoding transcription factors implicated in 
T cell differentiation were upregulated in Arg2–/– cells. Finally, genes encoding various cell surface proteins, 
including the activation marker CD69 (Cd69), were upregulated in Arg2–/– cells. Conversely, the genes encoding 
2 negative costimulatory receptors, CTLA-4 (Ctla4) and PD-1 (Pdcd1), were downregulated in Arg2–/– cells.
A similar overall picture was obtained by means of  a proteomic analysis performed 72 hours after 
activation (Figure 4G). Proteins upregulated in the Arg2–/– cells versus WT cells included the transcription 
factors T-bet, Eomes, Runx2, and molecules exerting key CD8+ T cell effector functions (granzymes, per-
forin, IFN-γ, TNF-α), whereas inhibitory receptors were downregulated (CTLA-4, PD-1, Lag3). These 
results indicate that activated Arg2–/– CD8+ T cells acquire a more robust effector phenotype than their WT 
counterparts and are likely to be less sensitive to negative checkpoint stimuli.
Improved antitumor response by adoptively transferred CD8+ T cells lacking Arg2. To assess the impact of  
a T cell–specific deletion of  Arg2 on tumor control in vivo, we next performed adoptive transfer experi-
ments in which OT-I or Arg2–/– OT-I T cells were transferred into MC38-OVA tumor-bearing WT hosts, 
which were then immunized 1 day later with OVA257-264 and CpG-B. As T cell donors, we used mixed 
BM chimeras generated by reconstituting irradiated WT recipients with a 9:1 mixture of  Rag2–/– BM 
and either OT-I or Arg2–/– OT-I BM (Figure 5A). This strategy was used to ensure that results could be 
attributed to a T cell–intrinsic deficiency of  Arg2 rather than to potential confounding effects resulting 
from development of  the T cells in a full Arg2-deficient background. The CD45.1 marker was used to ver-
ify reconstitution in the mixed BM chimeras (Supplemental Figure 5, A–F). The transferred Arg2–/– OT-I 
cells were markedly superior at reducing tumor growth relative to Arg2-proficient OT-I cells (Figure 5B), 
thereby leading to prolonged mouse survival (Figure 5C). Arg2–/– OT-I cells actually induced the com-
plete elimination of  tumors in a greater proportion of  mice; after 40 days, 44% (7 of  16) of  mice having 
received Arg2–/– OT-I cells were tumor free, compared with only 12% in mice having received OT-I cells 
(Figure 5D). Importantly, using OT-I cells derived from mixed BM chimeras (Figure 5, A–D) yielded 
results comparable with those obtained using OT-I cells isolated directly from germline Arg2–/– OT-I and 
OT-I mice (Figure 5E), indicating that the enhanced antitumor function of  Arg2–/– OT-I T cells is indeed 
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Figure 3. Arg2–/– CD8+ T cells exhibit 
enhanced activation dynamics and 
cytokine production. In all panels, CD8+ T 
cells isolated from naive WT or Arg2–/– OT-I 
mice were activated in vitro with αCD3ε and 
αCD28 antibodies. (A) The representative 
contour dot plots show FACS analyses of 
CD62L expression after 1 hour, 2 days, and 
3 days of activation. (B) The bar graphs 
show the percentage of CD62Llo cells at 
indicated time points. (C) The bar graphs 
show the percentage of CD69hi cells after 24 
hours of activation in medium containing 
the indicated concentrations of L-arginine. 
(D) IFN-γ was quantified by ELISA in cell 
supernatants after 24 hours of stimula-
tion. (E) Expression of IFN-γ was assessed 
after 24 hours of activation by intracellular 
FACS staining. (F–I) Time-course qPCR 
experiments were performed to quantify 
the induction of (F) Ifng, (G) Il2, (H) Nos2, 
and (I) Gapdh mRNAs (n = 4). Results 
were (B and C) pooled from 2 independent 
experiments or (D and I) are representative 
of 3 independent experiments. Data is rep-
resented as mean ± SEM throughout. *P < 
0.05, **P < 0.01, ***P < 0.001, and ****P < 
0.0001 (B–E: 2-tailed Student’s t test) (F–I: 
2-way ANOVA).
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Figure 4. Activated Arg2–/– CD8+ T cells exhibit faster and stronger upregulation of key genes implicated in CD8+ T cell function. WT or Arg2–/– OT-I CD8+ 
T cells were activated in vitro with αCD3ε and αCD28 antibodies, and their transcriptomes were characterized by RNA-seq after 0, 2, 6, 12, and 24 hours of 
activation. (A) The graphs show the results of a GSEA performed for the indicated gene sets in cells activated for 6 hours. The normalized enrichment score 
(NES) is indicated. (B–E) The volcano plots represent the comparisons between the transcriptomes of WT and Arg2–/– CD8+ T cells at the indicated time 
points: fold-change (FC) in mRNA expression in Arg2–/– relative to WT cells is plotted as a function of the P value (Wald test, GLM in edgeR). Dots corre-
sponding to mRNAs for key functionally relevant genes are indicated. (F) The heatmap represents the FC in mRNA expression in Arg2–/– relative to WT cells, 
in all time points analyzed, for selected genes grouped according to the indicated functionally relevant categories. (G) WT or Arg2–/– OT-I CD8+ T cells were 
activated in vitro with αCD3ε and αCD28 antibodies, and the proteome was analyzed after 72 hours by LC-MS. The volcano plot represents comparisons 
between the proteomes of WT and Arg2–/– CD8+ T cells: FC in protein expression in Arg2–/– relative to WT cells is plotted as a function of the P value (2- tailed 
Welch t test). Dots corresponding to key functionally relevant proteins are indicated. P values have been adjusted using the Benjamini-Hochberg procedure.
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Figure 5. Endogenous Arg2 in CD8+ T cells is a cell-intrinsic regulator of their antitumor function. (A) The scheme illustrates the experimental 
setting used in panels B–D, F, and G. Five days prior to adoptive T cell transfer, 0.5 × 106 MC38-OVA cells were implanted s.c. into WT host. At day 0, 
1 × 106 to 1.5 × 106 CD8+ T cells isolated from naive WT or Arg2–/– mixed BM chimeric mice were adoptively transferred into the tumor-bearing mice. 
Control mice received no T cells. One day after T cell transfer, mice were immunized s.c. with OVA257–264 and CpG-B. (B) Tumor growth, (C) mouse sur-
vival, and (D) tumor clearance rates at day 40 were assessed (n = 12–15). (E) Tumor growth was assessed using a setting identical to that in A, except 
that tumor-bearing mice received naive or 6-day preactivated CD8+ T cells derived from WT or Arg2–/– OT-I mice (n = 11–12). Only mice transferred with 
naive cells were primed in vivo by s.c. immunization with CpG-B and OVA257–264. (F and G) t-SNE plots showing the FlowSOM-guided metaclustering 
gated on (F) TCRb+ T cells present in the TdLNs or gated on (G) CD45+ cells infiltrating the tumors of WT tumor-bearing mice having received WT (left) 
or Arg2–/– (right) OT-I cells. (B–E) Results were pooled from 2 or 3 independent experiments. Data is represented as mean ± SEM throughout. *P < 
0.05, **P < 0.01, and ****P < 0.0001 (B and E: 2-way ANOVA) (C: log-rank Mantel-Cox test) (D: Fisher’s exact test).
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cell intrinsic. Additionally, enhanced control of  tumor growth by Arg2–/– OT-I cells relative to OT-I cells 
was evident both when transferred cells were activated in vivo by immunization and when the cells were 
preactivated in vitro for 6 days prior to transfer (Figure 5E). This increased tumor control by preactivat-
ed Arg2–/– OT-I cells reinforces the phenotypic data indicating that in vitro–activated Arg2–/– OT-I cells 
exhibit enhanced effector functions compared with OT-I cells.
To clarify the relative impacts on antitumor immune responses of  the transferred OT-I and Arg2–/– OT-I 
cells, we performed high-dimensional flow cytometric analyses of  global TdLNs and TIL populations at 
day 8 after OT-I transfer (Figure 5, F and G, and Supplemental Figure 6, A–D). In both TdLNs and tumors, 
the overall compositions of  the lymphocyte populations were similar between mice having received OT-I 
and Arg2–/– OT-I cells. Furthermore, OT-I and Arg2–/– OT-I T cells were enriched in the tumors to similar 
extents relative to the TdLNs. Taken together, these results suggest that the enhanced antitumor potential 
of  Arg2–/– OT-I cells is a cell-intrinsic property that is independent of  their expansion and tumor-homing 
properties, or of  indirect repercussions on other lymphoid cells.
To further investigate the impact of  Arg2 deficiency on the spatiotemporal dynamics of  tumor-specif-
ic T cell responses, equal numbers of  naive OT-I and Arg2–/– OT-I CD8+ T cells were cotransferred into 
MC38-OVA tumor-bearing mice, and their distribution in the hosts was assessed by flow cytometry in key 
locations and at different time points after OVA257–264 immunization (Figure 6A). The CD45.1 marker was 
used to discriminate both OT-I (CD45.1+/+) and Arg2–/– OT-I (CD45.1+/–) cells from endogenous cells (Fig-
ure 6B). The overall dynamics were similar for OT-I and Arg2–/– OT-I cells (Figure 6, C and D). At early 
stages (3–4 days), both cell types were most abundant in the TdLNs and to a lesser extent in the spleen 
and nondraining LNs (ndLNs). They then accumulated in the blood (peaking at day 6) and infiltrated the 
tumors (as of  day 6). The ratio between OT-I and Arg2–/– OT-I cells was close to 1:1 in the TdLNs and 
tumors until day 8 (Figure 6E). By day 15, however, Arg2–/– OT-I cells were markedly more frequent than 
OT-I cells in both the TdLNs and tumors (Figure 6E), suggesting that they mount a more persistent antitu-
mor response than their WT counterparts.
We next assessed the relative proportions of  OT-I and Arg2–/– OT-I cells present in the viable and dead 
cell fractions (Figure 6F) found in TdLNs or in tumors at days 3, 6, and 15. Inside the tumors, Arg2–/– OT-I 
cells were overrepresented in the dead cell fraction relative to the viable fraction at all 3 time points (Figure 
6G). In contrast, no preferential death of  Arg2–/– OT-I cells was evident in the TdLNs (Figure 6H). Enhanced 
accumulation of  dead Arg2–/– OT-I cells in the tumors suggests that these cells are capable of  mounting a 
more active antitumor response associated with increased activation-induced cell death at the effector site.
To confirm the alterations in functionally relevant markers observed in vitro, we next examined IFN-γ 
and PD-1 expression on OT-I and Arg2–/– OT-I cells in both TdLNs and tumors at day 7. Frequencies of  
IFN-γ+ cells were greater in Arg2–/– OT-I cells in both the TdLNs and tumors (Figure 6I). Additionally, 
PD-1 expression was significantly lower on Arg2–/– OT-I cells in the tumors (Figure 6J). Increased IFN-γ 
and reduced PD-1 expression by Arg2–/– OT-I cells in the tumor was consistent with the in vitro data, and 
show that Arg2–/– cells develop more sustained responses, even in the context of  the TME.
To further investigate the increase in T cell persistence, we next compared the memory formation and 
survival of  OT-I and Arg2–/– OT-I cells transferred into OVA257–264 immunized mice. Twenty-eight days after 
immunization, OT-I and Arg2–/– OT-I cells were found at comparable frequencies in the dLNs, ndLNs, and 
spleens (Figure 6K). However, the Arg2–/– cells exhibited a greater proportion of  CD44hiCD62Lhi central 
memory T cells (Tcm) in the dLN, but not in the ndLN or spleen (Figure 6L). Expression of  the lymphoid 
tissue homing receptor CCR7 by Arg2–/– cells remained similar to their WT counterparts in both the LN 
and spleen (Figure 6M). Taken together, these results suggest that Arg2 deficiency leads to increased devel-
opment of  Tcm rather than to preferential recruitment to secondary lymphoid organs.
Arg2–/– CD8+ T cells are more resistant to an arginine-poor TME. Intratumoral arginine depletion by increased 
arginase activity contributes to creating an immunosuppressive TME. To determine if  the intracellular deletion 
of Arg2 might compensate for the extracellular arginine depletion and render Arg2–/– CD8+ T cells more resistant 
to this immunosuppressive mechanism (i.e., to an arginase-active TME), we generated MC38-OVA cells over-
expressing Arg2. Strong overexpression was documented at the mRNA and protein levels (Figure 7, A and B). 
Control experiments demonstrated that Arg2 overexpression did not affect proliferation of the tumor cells in 
cell cultures (Figure 7C) or tumor growth in Rag2–/– mice, which lack an adaptive immune system (Figure 7D). 
In contrast, the Arg2-overexpressing tumors grew more rapidly in WT mice, confirming the immunosuppres-
sive effect of Arg2 overexpression on the adaptive antitumor immune response (Figure 7E). We next assessed 
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Figure 6. Arg2 deletion enhances the persistence of antitumor CD8+ T cell responses and increases differentiation into Tcm cells. (A) The scheme 
illustrates the experimental setting used in panels B–H. The approach was similar to that in Figure 5A, except that tumor-bearing mice were 
adoptively transferred with a 1:1 mix of naive WT and Arg2–/– cells (1 × 106 to 1.3 × 106 total cells). (B) The representative contour plots illustrate the 
approach used in C and D to use CD45.1 staining to discriminate between WT CD45.1+/+ and Arg2–/– CD45.1+/– CD8+ OT-I cells. (C and D) The graphs sum-
marize the spatiotemporal distribution of adoptively transferred WT (C) or Arg2–/– (D) CD8+ OT-I cells during the course of the antitumor response (n 
= 10). (E) The graphs show the percentage of Arg2–/– cells within the total transferred OT-I cell populations found at the indicated time points in the 
TdLNs and tumors (n = 10). (F) The representative contour plots illustrate how viable and dead fractions were quantified 15 days after transfer within 
the cotransferred WT and Arg2–/– CD8+ OT-I cell populations in the TdLNs (top) and tumor infiltrates (bottom). (G and H) The graphs summarize the 
Arg2–/– versus WT CD8+ OT-I cell ratios found at different time points within the viable and dead cell fractions in tumors (G) or in TdLNs (H). (I and J) 
In the setting illustrated in Figure 5A, flow cytometry was used 8 days after transfer to quantify the frequencies of IFN-γ+ cells in WT and Arg2–/– OT-I 
cell populations (I) or the expression of PD-1 by WT and Arg2–/– OT-I cells (J) in TdLNs and tumor infiltrates. (K–M) WT CD45.1+/+ or Arg2–/– CD45.1+/– 
CD8+ OT-I cells were adoptively transferred into naive WT hosts, which were immunized with CpG-B and OVA257–264 24 hours later. Cell frequency (K), 
central/effector memory differentiation (L), and CCR7 (M) were analyzed by flow cytometry in OT-I cells found in spleen (Spl), draining (dLN), and 
nondraining lymph nodes (ndLN) 28 days after immunization. Violin plots (K, L, M) show the median and quartiles. (C–E and G–M) Results were 
pooled from 2 or 3 independent experiments. *P < 0.05, **P < 0.01, and ***P < 0.001 (G–M: 2-tailed Student’s t test) (E: 2-tailed Welch’s t tests)
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susceptibility of the Arg2-overexpressing tumors to control by transferred OT-I and Arg2–/– OT-I cells (Figure 7, 
F and G). The Arg2–/– OT-I cells were more efficient than OT-I cells at inhibiting the growth of both control and 
Arg2-overexpressing tumors, although they were, as expected, less efficient at suppressing growth of the latter. 
Arg2–/– OT-I cells, thus, have an advantage over OT-I cells in being able to function in an immunosuppressive 
TME exhibiting reduced arginine availability.
CD8+ T cell–intrinsic Arg2 deficiency synergizes with PD-1 blockade. Tumors can induce exhaustion of  
tumor-infiltrating T cells both by subverting the coinhibitory PD-1/PD-L1 checkpoint axis (18) and by 
establishing competition for essential molecular nutrients, including arginine (19). Given that Arg2–/– T cells 
exhibit an enhanced antitumor function, even slightly superior in an arginine-poor microenvironment (Fig-
ure 3C, and Figure 7, F and G), we assessed whether this feature might be potentialized by PD-1 blockade.
Figure 7. Arg2–/– CD8+ T cells are partially protected against an immunosuppressive TME induced by overexpression 
of arginase 2 in tumor cells. Quantification by (A) Western blot of Arg2 protein and (B) qPCR of Arg2 mRNA abundance 
in control (parental or pWPI-vector transduced) and Arg2-overexpressing MC38-OVA cells. (C) An MTS-based assay was 
used to compare the in vitro proliferation of control (pWPI-transduced) and Arg2-overexpressing tumor cells (n = 3). (D 
and E) Growth of control (pWPI-transduced) and Arg2-overexpressing tumors was compared in (D) Rag2–/– (n = 10–11) 
or (E) WT hosts (n = 15–16). (F and G) WT mice were implanted with control (pWPI-transduced) or Arg2-ovexpressing 
tumors; when tumors were palpable (after 5 days), WT or Arg2–/– OT-I cells were adoptively transferred, and mice were 
immunized the next day with CpG-B and OVA257–264 (n = 14). Tumor-bearing mice receiving no OT-I cells were used as 
controls. To improve visualization, tumor growth curves are shown separately for (F) groups having received no cells or 
WT OT-I cells and (G) groups having received WT or Arg2–/– OT-I cells. (B) Results are representative of 2 independent 
experiments or (C–G) were pooled from 2 or 3 independent experiments. (C) Statistical analysis was performed using 
2-way ANOVA. Data is represented as (B) mean ± SD or (D–G) as mean ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001 
(B: 2-tailed Student’s t test) (C–G: 2-way ANOVA).
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In a first approach, WT and Arg2–/– mice bearing MC38-OVA tumors were treated with isotype control or 
blocking anti–PD-1 antibodies. Compared with the individual impacts observed for Arg2 deficiency or PD-1 
blockade alone, PD-1 blockade in Arg2–/– mice led to a dramatic reduction in tumor growth, markedly pro-
longed mouse survival, and an increased rate of tumor clearance, with 75% tumor-free individuals in anti–
PD-1–treated Arg2–/– mice versus 37% for PD-1 blockade alone (P = 0.732) and 14% for Arg2 deficiency alone 
Figure 8. Tumor growth is inhibited synergistically by PD-1 blockade and either germline or CD8+ T cell–intrinsic deletion of Arg2. (A–C) MC38-OVA cells 
were implanted s.c. into WT or Arg2–/– hosts, which were then treated with 200 μg i.p. injections of isotype control (IgG2a) or anti–PD-1 antibodies after 
8, 11, and 14 days (green arrows). The results show (A) tumor growth, (B) mouse survival, and (C) tumor clearance rates at day 40 after tumor injection 
(n = 14–16). (D) The scheme illustrates the experimental setting used in panels E and F. WT mice were implanted with MC38-OVA cells; when tumors 
were palpable (after 5 days), WT or Arg2–/– OT-I cells were adoptively transferred, and mice were immunized the following day with OVA257–264 and CpG-B. 
Finally, the mice were treated with 200 μg i.p. injections of isotype control (IgG2a) or anti–PD-1 antibodies at days 8, 11, and 14 after T cell transfer (green 
arrows). Mice receiving no OT-I cells were used as controls. The results show (E) tumor growth, (F) mouse survival, and (G) tumor clearance rates at day 60 
after tumor injection (n = 14–16). Isotype control data not shown in F, and in E, data were split into 2 graphs for clarity. (A–F) Results were pooled from 2 
independent experiments. (A and E) Statistical analysis was performed using 2-way ANOVA. (A and E) Data is represented as mean ± SEM. *P < 0.05, ***P 
< 0.001, and ****P < 0.0001 (A and E: 2-way ANOVA) (B and F: log-rank Mantel-Cox test) (C and G: Fisher’s exact test). 
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(P < 0.001) (Figure 8, A–C). In a second approach, we explored the benefit of combining adoptive Arg2–/– OT-I 
transfer and PD-1 blockade in WT tumor-bearing mice (Figure 8D). In this setting, we again observed synergy 
between the T cell–intrinsic Arg2 deficiency and PD-1 blockade. Compared with mice that had received only 
Arg2–/– OT-I cells or anti–PD-1 antibodies, those that were submitted to the combined treatment exhibited a 
stronger reduction in tumor growth, prolonged survival, and increased tumor clearance rates (Figure 8, E–G).
Discussion
Studies on the role of  L-arginine metabolism in immune responses have focused almost exclusively on 
the requirement of  sufficient extracellular arginine availability for effective T cell activation and on the 
immunosuppressive effect of  Arg1-mediated arginine depletion, particularly for immunosuppression of  
antitumor T cell responses in the TME. In contrast, the roles of  Arg2-mediated arginine metabolism in 
immune responses have remained largely unexplored. We show here — using in vivo murine tumor mod-
els, T cell transfer approaches, flow cytometry, proteomics, and transcriptomics — that genetic ablation of  
Arg2 expression in CD8+ T cells strengthens, in a cell-autonomous manner, their effector functions and 
their ability to mount more robust and persistent antitumor responses.
In agreement with the enhanced antitumor function of  Arg2-deficient CD8+ T cells, CD8+ T cell–
depletion experiments demonstrated that impaired tumor growth in Arg2-deficient mice could be attributed 
largely to increased antitumor CD8+ T cell responses. Interestingly, however, depletion of  CD4+ T cells 
selectively improved tumor control in Arg2-deficent mice, indicating an enhanced regulatory activity exert-
ed by CD4+ T cells in these mice. Remarkably, we also observed altered functional properties of  in vitro–
activated Arg2–/– OT-II cells (data not shown), suggesting that Arg2 deficiency affects the function of  both 
CD4+ and CD8+ T cells. Furthermore, we have previously shown that Arg2 also regulates the function of  
DCs (13). It is, therefore, unlikely that the phenotype observed in germline Arg2–/– mice can be attributed 
entirely to altered CD8+ T cell responses.
Most investigations of  the influence of  arginine metabolism on T cells were based on interventions 
affecting extracellular arginine concentrations. However, extracellular and intracellular arginine pools 
are not freely interchangeable (20), which implies that the extracellular arginine supply may not serve as 
a reliable proxy for intracellular arginine availability. We demonstrate here that disrupting intracellular 
hydrolysis of  arginine in CD8+ T cells improves their activation and effector functions; in vitro–acti-
vated Arg2–/– T cells displayed more rapid and robust activation, based on CD62L shedding and CD69 
upregulation, and enhanced effector functions, including increased perforin, granzyme, FasL, and cyto-
kine (IFN-γ and IL-2) expression. These enhanced properties of  Arg2-deficient T cells were found to be 
independent of  extracellular arginine concentrations in vitro, emphasizing the critical importance of  
intracellular arginine pools relative to the extracellular arginine supply.
Adoptively transferred Arg2–/– OT-I CD8+ T cells were more effective than OT-I CD8+ T cells at 
controlling tumor growth in vivo, even when tumors strongly overexpressed Arg2. The disruption of  
intracellular arginine catabolism, thus, partially protects tumor-infiltrating T cells against the immuno-
suppressive effect of  arginine depletion in the TME. Taken together, these observations indicate that the 
intracellular homeostasis of  arginine plays a pivotal role for the antitumor fitness of  CD8+ cytotoxic T 
lymphocytes (CTLs) and that the intracellular arginine pool is even more critical than the extracellular 
arginine supply for controlling CD8+ T cell responses in vivo.
Previous studies have found increased intracellular arginine levels in activated Arg2–/– T cells, indicative 
of  enzymatic activity in these cells (16). Furthermore, as observed for Arg2–/– mouse T cells, we found that 
ex vivo treatment of  human PBMC–derived T cells with arginase inhibitors led to an increased activation 
phenotype, very similar to that observed for mouse Arg2-deficient T cells. It is, therefore, possible that 
the elevated intracellular arginine pool, which results from the loss of  Arg2 activity, is responsible for the 
potentiated functional properties of  Arg2–/– T cells and inhibitor-treated human T cells.
Although murine Arg2–/– CD8+ T cells exhibited accelerated and more robust activation kinetics 
in vitro, their proliferative capacity was not altered. Furthermore, the early spatiotemporal patterns 
of  WT and Arg2–/– CD8+ T cell responses were very similar in vivo. In particular, no preferential 
amplification of  Arg2–/– CD8+ T cells was evident in vivo; at the peak of  the antitumor response, WT 
and Arg2–/– CD8+ T cells were present in equivalent numbers in both the TdLNs and tumors. There-
fore, the T cell–intrinsic Arg2 deficiency does not seem to affect the priming or amplification phases 
of  CD8+ T cell responses. Instead, several lines of  evidence point to a more robust and persistent 
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effector response. First, Arg2–/– CD8+ T cells acquire a more robust effector phenotype, both in vitro 
and in vivo. Second, both in vitro–activated and tumor-infiltrating Arg2–/– CD8+ T cells exhibit lower 
expression of  inhibitory checkpoint regulators, suggesting that Arg2–/– T cells become less exhausted 
or are less susceptible to immunologic inhibition. Third, tumor-infiltrating Arg2–/– CD8+ T cells die 
preferentially in the tumor compared with WT CD8+ T cells, which, in combination with the increased 
cytotoxic activity described in Arg2–/– hosts, suggests that they mount a more effective antitumor CTL 
response, leading to activation-induced cell death. Fourth, following the adoptive transfer of  equal 
numbers of  in vitro–activated WT and Arg2–/– CD8+ T cells, the latter showed a superior ability to 
mount effective antitumor responses. Fifth,at later stages of  the antitumor response, Arg2–/– CD8+ T 
cells became dominant over cotransferred WT CD8+ T cells in both the TdLNs and tumors, suggesting 
that Arg2-deficient cells mount more sustained antitumor responses. Finally, although it remains a 
subject for future studies, Arg2 deficiency in CD8+ T cells enhanced the formation of  long-lived CD8+ 
Tcm, suggesting that the more robust and durable response mounted by Arg2-deficient CD8+ T cells 
could be due to enhanced memory formation, as a more sustained source of  effector cells.
Immune checkpoint (PD-1, CTLA-4) blockade has become the benchmark treatment for cancer 
therapy (21). We observed strong synergy between the inhibition of  tumor growth induced by systemic 
Arg2 deficiency and anti–PD-1 therapy. We therefore hypothesize that reduced PD-1 expression by 
Arg2–/– T cells might render them less sensitive to inhibition by PD-L1/2 in the TME and allow them 
to be more readily revigorated by PD-1 blockade. Interestingly, a very similar synergistic inhibition of  
tumor growth was observed when PD-1 blockade was combined with the systemic administration of  
an arginase inhibitor (22). Promising results were also obtained by combining dietary arginine supple-
mentation with PD-L1 blockade (23). Moreover, a strong synergistic inhibition of  tumor growth was 
observed when we combined PD-1 blockade with the adoptive transfer of  tumor-specific Arg2–/– CD8+ 
T cells. Taken together, these results imply that arginine metabolism in T cells and the PD-1/PD-L1 
axis control antitumor T cell responses via nonredundant mechanisms, thereby providing a strong 
rationale for combining immunotherapies based on immune checkpoint blockade with the selective 
targeting of  Arg2 in T cells.
Our study highlights a critical T cell–intrinsic role of  Arg2 in modulating the efficacy of  immune 
responses, especially CD8+ T cell–mediated antitumor responses, and has major implications for the 
field of  cancer therapy. The previously unanticipated beneficial impact of  blocking detrimental arginase 
activity in T cells could warrant the reassessment or redirection of  therapeutic strategies based on the 
systemic administration of  arginase inhibitors. Selective interference with Arg2 expression or activity 
in T cells could also form the basis for novel therapeutic modalities aimed at improving existing cancer 
immunotherapies, particularly CAR T cell and TIL transfer therapies. In particular, the abrogation of  
Arg2-mediated arginine catabolism could favor the persistence of  T cell responses in such therapies.
Human tumors often upregulate arginase activity to suppress immune control via arginine depletion 
in the TME. In mouse models, Arg2-overexpressing tumors were also found to grow more aggressively 
because they inhibited adaptive immune responses. Our observation that Arg2-deficient CD8+ T cells 
exhibit an enhanced resistance to the immunosuppressive effect of  reduced extracellular arginine avail-
ability finally suggests that interfering with arginine metabolism in T cells could be particularly relevant 
for improving the treatment of  highly immunosuppressive arginase-rich solid tumors.
Methods
Animal experimentation. Age- and sex-matched C57BL/6 mice were purchased from Charles River Laborato-
ries. Arg2–/–, miR155–/–, and Rag2–/– mice were purchased from The Jackson Laboratory (020286, 007745, and 
008449, respectively) and bred at Charles River Laboratory. Transgenic OT-I (OT-Itg) CD45.1+/+ mice were pro-
vided by Doron Merkler (University of Geneva) and were bred and crossed with Arg2–/– mice in our facility 
(University of Geneva). β2m–/– mice (002087, The Jackson Laboratory) were provided by Greta Guarda (Uni-
versità della Svizzera italiana). Unless stated otherwise, mice were bred under specific pathogen-free conditions 
and acclimatized for more than 1 week prior to experiments.
Mouse genotyping and immunophenotyping. PCR amplification of  relevant loci was performed using 
the primers listed in Supplemental Table 2. CD45.1 and CD45.2 typing was done by flow cytometry 
(clones A20 and 104; BioLegend), and presence of  the OT-I transgene was assessed using anti-Vα2 and 
anti-Vβ5 antibodies (clones B20.1 and MR9-4; BioLegend).
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Mouse histopathological analyses. Necropsies and histological evaluation were performed according to 
standard procedures by a board-certified veterinary pathologist. Organ weights were taken using a preci-
sion scale to the nearest thousandth of  a gram (Mettler Toledo ME 802). Organ samples for histology were 
fixed in 4% paraformaldehyde for 24 hours. Head, spinal cord, sternum, femur, and knee joint samples 
were decalcified for 6–12 hours. For histology, all organs were routinely processed, embedded in paraffin, 
cut at 3-μm thickness, and stained with H&E. The histopathologic examination was performed in a blinded 
fashion by a European board-certified veterinary pathologist.
Cell lines. B16-OVA and MC38-OVA cells were maintained in RPMI-1640-Glutamax medium supple-
mented with 10% FBS, 50 U/mL penicillin, 50 μg/mL streptomycin, 1 mM sodium pyruvate, and 50 μM 
β-mercaptoethanol and under geneticin selection (0.4 mg/mL G418). All reagents were purchased from 
Thermo Fisher Scientific. B16-OVA and MC38-OVA were provided by Stéphanie Hugues (University of  
Geneva) and Pedro Romero (University of  Lausanne), respectively.
Mouse tumor models. In all tumor experiments, 0.5 × 106 B16-OVA or MC38-OVA cells resuspended in 
PBS were injected s.c. into the back of  host mice. Unless stated otherwise, 6- to 12-week-old female mice 
were used for experiments, and tumors were allowed to grow for different periods of  time according to 
specific experimental designs. Tumor size was quantified using a caliper, and tumor volume was calculated 
using a rational ellipse formula (α2 × β × π/6, where α is the shorter axis and β is the longer axis). Excised 
tumors were weighed postmortem. For flow cytometry analyses, tumors were minced and processed through 
a 70-μm nylon mesh and digested with Collagenase D and DNAse I (Roche) in HBSS (Thermo Fisher Scien-
tific) for 40 minutes at 37°C. TdLNs were processed through a 70-μm nylon mesh. In survival experiments, 
mice were withdrawn from the study after tumors had reached a volume greater than 1,200 mm3.
Arg2 overexpression in tumor cells. Arg2 cDNA was PCR amplified and cloned into the bicistronic lentiviral 
pWPI vector, which contains a GFP expression cassette for assessing transduction efficiency (13). Lentivi-
ral particles were generated in HEK293T cells, and tumor cells were subsequently transduced (13, 19) and 
FACS sorted on the basis of  GFP expression using a FACS AriaII (Becton Dickinson ). Arg2 overexpression 
was assessed by Western blotting and by real-time PCR, as described below. Protein extracts were fractionat-
ed by SDS-PAGE, and Western blotting was performed using anti–mouse Arg2 (sc-20151; Santa Cruz Bio-
technology) and anti–β-actin (sc-47778; Santa Cruz Biotechnology). Tumor cell in vitro proliferation assays 
were performed using CellTiter 96 AQueous One Solution (Promega) according to manufacturer’s instructions.
BM chimeras. One day prior to reconstitution, recipient mice were irradiated with 2 consecutive subleth-
al doses of  500 cGy. BM was extracted from the tibiae and femurs of  donor mice by flushing with PBS-ED-
TA 0.2 mM and then gently dissociated through a 70-μm nylon mesh. For BM chimeric mice 5 × 106 to 10 
× 106 cells were injected i.v. into recipient mice. For mixed BM chimeric mice, Rag2–/– BM cells were mixed 
at 9:1 ratio with BM cells from either OT-Itg CD45.1+/+ or Arg2–/– OT-Itg CD45.1+/– mice, and a total of  5 × 
106 to 10 × 106 cells were injected i.v. into WT recipient mice. The extent of  reconstitution was assessed by 
flow cytometric analysis of  blood cells after at least 8 weeks after BM transfer.
T cell isolation. Total CD8+ or CD4+ T cells from splenic and LN single cell suspensions were purified 
using a CD8a+ or CD4+ T Cell Isolation Kit (Miltenyi Biotec) and subsequently separated by AutoMACS 
or LS Columns (Miltenyi Biotec). Cell purity (95%) was confirmed by flow cytometry. Human PBMCs 
were isolated from buffy coats using Ficoll-Paque gradients, and total T cells were enriched using EasySep 
Human T Cell Isolation Kit (Stemcell Technologies).
In vivo killing assays. In assays with preimmunized mice, WT and Arg2–/– mice were immunized by i.p. 
injection of  100 μg of  endotoxin-free OVA protein (Hyglos) and 50 μg of  CpG-B ODN 1826 (Eurogentec) per 
mouse. Six days later, target splenocytes were harvested from naive WT mice, loaded or not with OVA257–264 
peptide (Invivogen), and labeled with either 2.50 μM (peptide-loaded cells) or 0.25 μM (unloaded cells) of  
CTV (Molecular Probes). Cells were then counted and mixed at 1:1 ratio in PBS, and 2 × 106 to 5 × 106 total 
target splenocytes were i.v. injected into preimmunized and naive mice. Twenty-four hours later, spleens were 
harvested, and splenocyte suspensions were analyzed by flow cytometry. Percentages of  specific in vivo killing 
were calculated as (1 – [% CTVlo naive/% CTVhi naive]/[% CTVlo immunized/% CTVhi immunized]) × 100.
In assays with tumor-bearing mice, WT and Arg2–/– mice were implanted with tumors cells as described 
above. After 11 days, each tumor-bearing mouse received 2.4 × 106 to 6.0 × 106 total target splenocytes 
labeled as above with CTV. Twenty-four hours later, ipsilateral TdLNs and contralateral ndLNs were har-
vested, and single cell suspensions were analyzed by flow cytometry. The in vivo killing ratio was calculated 
as (% CTVlo TdLN/% CTVhi TdLN)/(% CTVlo ndLN/CTVhi ndLN).
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For NK cell cytotoxicity assays, WT and Arg2–/– naive mice were i.v. injected with a 1:1 mixture of  WT 
and β2m–/– splenocytes (4 × 106 total per mouse) labeled with 2.50 μM (WT) or 0.25 μM (β2m–/–) CTV. Twen-
ty-four hours later, spleens were harvested and processed through 70-μm nylon mesh, and single cell sus-
pensions were analyzed by flow cytometry. The in vivo killing ratio was calculated as (% CTVlo/% CTVhi).
In vivo depletion and PD-1 blockade. In CD4+ and CD8+ T cell depletion experiments, mice received 
i.p. injections of  relevant antibodies at days –3, –1, +1, +4, +8, +11, +15, and +18, relative to the day of  
tumor injection, at a dose of  4 mg/kg per mouse diluted in 100 μL of  pH-matched PBS (according to the 
manufacturer’s recommendations). The antibodies used were: anti–CD4 IgG2b antibody (clone GK1.5) or 
IgG2b isotype control antibody (clone LTF-2); and anti–CD8α IgG2a antibody (clone 53-6.72) or IgG2a 
isotype control antibody (clone 2A3). In PD-1 blockade experiments, tumor-bearing mice received i.p. 
injections of  the relevant antibodies at days +8, +11, and +14 after tumor injection at a dose of  200 μg per 
mouse diluted in 100 μL of  pH-matched PBS (according to manufacturer’s recommendations). The anti-
bodies used were: anti–PD-1 IgG2a antibody (clone RMP1-14) or IgG2a isotype control antibody (clone 
2A3). All antibodies were purchased from BioXCell.
Adoptive T cell transfer in tumor-bearing mice. Five days after tumor implantation, each MC38-OVA 
tumor-bearing WT mouse received 1 × 106 to 2 × 106 OT-Itg CD45.1+/– or Arg2–/– OT-Itg CD45.1+/– 
CD8+ T cells by i.v. injection in PBS. One day later, hosts were immunized with 15 μg OVA257–264 
peptide and 50 μg CpG-B ODN 1826 per mouse. Mice were sacrificed at the indicated time points, 
relevant LNs and tumors were harvested, blood samples were collected when applicable, and samples 
were processed as described above. In adoptive cotransfer experiments, OT-Itg CD45.1+/– and Arg2–/– 
OT-Itg CD45.1+/– were counted and mixed at 1:1 ratio, and 1 × 106 CD8+ T cells were i.v. injected into 
each MC38-OVA tumor-bearing mouse. Mixed BM chimeric mice were used as donors of  the OT-Itg 
CD45.1+/– and Arg2–/– OT-Itg CD45.1+/– CD8+ T cells.
In vitro T cell activation. A total of  3 × 104 to 1 × 105 purified CD8+ or CD4+ T cells were cultured in 
NUNC MaxiSorp 96-well plates with RPMI 1640, GlutaMAX medium (Thermo Fisher Scientific) sup-
plemented with 5% FBS, 50 U/mL penicillin and 50 μg/mL streptomycin, and 50 μM β-mercaptoethanol 
(Thermo Fisher Scientific). T cells were activated with plate-coated anti-CD3ε (2 μg/mL, clone 145-2C11, 
BioXCell) and soluble anti-CD28 (2 μg/mL, clone 37.51, Becton Dickinson). For cytokine analyses, T cells 
were restimulated for 4.5 hours in complete RPMI 1640 with PMA (50 ng/mL; MilliporeSigma) and ion-
omycin (1 μg/mL), and in the presence of  1 μg/mL Golgi-plug and 1 μg/mL Golgi-stop (Becton Dickin-
son). To generate medium with reduced concentrations of  L-arginine, L-arginine and L-lysine free SILAC 
RPMI 1640 (Thermo Fischer Scientific) was supplemented with 0.2 mM of  L-lysine (Sigma-Aldrich) and 
the indicated amounts of  L-arginine (Sigma-Aldrich). Human cells were cultured in similar conditions as 
above, activated with plate-coated anti-CD3ε (2 μg/mL, clone OKT3, BioLegend) and soluble anti-CD28 
(2 μg/mL, clone 28.6, eBioscience) and in the presence or not of  ABH (MilliporeSigma), BEC (Milli-
poreSigma), CB-1158 (MedKoo), nor-NOHA (Merck-Millipore).
For the generation of  preactivated OT-I T cells, purified OT-I CD8+ T cells were cultured and activated 
as described above. At days 2 and 4, cells were split and cultured in fresh RPMI-complete in the additional 
presence of  250 U/mL murine IL-2 (Miltenyi Biotec). At day 6, cells were harvested and carefully counted 
for in vivo adoptive transfer.
RNA extraction and real-time PCR. Total RNA was extracted using peqGOLD TriFast following the 
manufacturer’s instructions (PeqLab). Glycogen was used as carrier. RNA purity and integrity were 
assessed by gel electrophoresis using a Bioanalyzer (Agilent) at the Genomics Platform of  the University 
of  Geneva, and RNA was quantified using a Qubit fluorometer. For real-time PCR, RNA was quantified 
using a NanoDrop 2000 (Thermo Fisher Scientific). Totals of  500 ng (miR155–/– and Arg2 overexpression 
experiments) or 200 ng (Arg2–/– experiments) were reverse transcribed using a SuperScript II reverse tran-
scriptase kit (Invitrogen) with random hexamer primers (Thermo Fisher Scientific) following the manufac-
turer’s instructions. Real-time PCR analyses were performed using iQ SYBR Green Supermix (Bio-Rad) 
in a CFX Connect Real-Time System (Bio-Rad). Expression levels were inferred from a standard curve 
generated with serial dilutions of  input cDNA, and expression was normalized to 18S rRNA or Gapdh 
mRNA (Arg2-overexpression experiments). Primers are listed in Supplemental Table 2.
ELISA. Cell supernatants were collected and frozen at the indicated time points. Secreted IL-2 and 
IFN-γ were measured in NUNC MaxiSorp 96-well plates using Ready-Set-Go! kits (88-7024-22 and 
88-7314-22, eBioscience), according to the manufacturer’s instructions. Analysis was done using a kinetic 
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microplate reader (Molecular Devices) at a 450-nm wavelength. A 4-parameter fit using a precalibrated 
standard curve was used for absolute quantification.
Flow cytometry. Samples of  peripheral blood were collected in FACS Buffer (PBS + 0.5% BSA + 5 mM 
EDTA), and erythrocytes were lysed using 1-step Fix/Lyse solution (eBioscience) after antibody labeling. 
Viable cell discrimination was done by staining with Zombie Yellow (BioLegend) or near–infrared radia-
tion (near-IR) fluorescence reactive dye (Molecular Probes) according to the manufacturer’s protocol. For 
high-dimensional analysis, viable cell discrimination was done by staining with Zombie Aqua (BioLegend) 
according to the manufacturer’s protocol. For proliferation assays, CTV staining was performed at 5 μM 
concentration for 15 minutes at 37°C in PBS. Prior to antibody staining, Fc receptors were blocked with anti-
CD16/CD32 antibody treatment (clone 2.4G2, eBioscience) for 10 minutes at 4°C. Extracellular staining was 
performed in FACS buffer (PBS + 0.5% BSA + 5 mM EDTA) for 15 minutes at 4°C. For intracellular anti-
gens, cells were fixed and permeabilized using Foxp3/Transcription Factor Staining Buffer Set (eBioscience) 
for 45 minutes at 4°C, and intracellular antigens were subsequently stained in permeabilization buffer for 45 
minutes at 4°C. For high-dimensional FACS analysis, the labeling of  the intracellular antigens was performed 
overnight at 4°C in permeabilization buffer. Extracellular and intracellular proteins were stained using the 
antibodies listed in Supplemental Table 3. Samples were analyzed on a Gallios (Beckman Coulter) or Attune 
NxT (Thermo Fisher Scientific) flow cytometer using appropriate filter sets and compensation controls. For 
high-dimensional FACS analysis, data were acquired on a FACSymphony (Becton Dickinson). Gates were 
assigned according to appropriate negative and fluorescence minus one (FMO) control populations.
L-Arginine mass spectrometry. Harvested tissues were snap frozen in liquid nitrogen and vacuum-dried 
overnight on a CentriVap (Labconco). Dry tissues were ground mechanically in liquid nitrogen, and 5 mg 
of  fine powder was used for amino acid extraction using ethanol/water/diethylether/pyridine (15:15:5:1) 
and ammonium hydroxide 2.1 × 10–3 N (chemical reagents purchased from MilliporeSigma), in the pres-
ence of  L-arginine-13C6,
15N4 hydrochloride standard (Cambridge Isotope Laboratories). For analysis of  
circulating arginine levels, tail vein blood samples were collected in sterile Microtainer tubes (1.5 mL; Bec-
ton-Dickinson), and serum was collected after 40 minutes of  clotting at room temperature and stored at 
–20°C until analysis. Subsequently, amino acids were extracted from 50 μL of  serum samples as described 
above for tissue samples. Extracts were dried in a CentriVap and stored at –80°C until analysis. Dried 
extracts were resuspended in 10 μL 0.1 % formic acid, 70 μL borate buffer (200 mM boric acid pH 8.8 
[with NaOH], 10mM tris [2-carboxyethyl]phosphine [TCEP], 1 mM ascorbic acid, 35.7 μM 13C15N-Va-
line) Boric acid, TCEP, and ascorbic acid were from MilliporeSigma; 13C15N-Valine was from Cambridge 
Isotope Laboratories. The mixture was sonicated for 5 minutes, and 20 μL of  10 mM AQC (6-aminoqui-
nolyl-N-hydroxysuccinimidyl carbamate, 2.85 mg/mL in acetonitrile; MilliporeSigma) was added. The 
sample was incubated for 15 minutes at 55°C with shaking (750 rpm) followed by overnight incubation at 
24°C. After incubation, the sample was centrifuged (400 g, 10 minutes), and the supernatant transferred to 
a new insert. Liquid chromatography–mass spectrometry (LC-MS) was performed using an Accela HPLC 
system coupled to a TSQ Vantage Triple Stage Quadrupole Mass Spectrometer (Thermo Fisher Scientif-
ic). A total of  10 μL was loaded onto a NUCLEOSHELL RP 18 column (particle size, 2.7 μm; length, 100 
mm; diameter, 2 mm) (MACHEREY-NAGEL) and a gradient was applied: solvent A, milliQ water + 0.1 
% formic acid (MilliporeSigma); solvent B, isopropanol (MilliporeSigma) + 0.1 % formic acid, at a flow 
of  300 μL/min. The quantification of  the metabolites was performed using multiple reaction monitoring 
(MRM). Area of  arginine was normalized to the internal L-arginine-13C6,
15N4 standard.
Proteomics. Cells were harvested, washed twice in D-PBS, and snap-frozen in liquid nitrogen. Frozen 
cell pellets were resuspended in a buffered solution containing 8 M urea. After reduction of  disulphide 
bonds and alkylation, samples were sonicated using a Bioruptor and digested with LysC (Fujifilm) and 
trypsin (MilliporeSigma), and peptides were purified using StageTips (24). Peptides were analyzed on a 
QExactive HF mass spectrometer coupled to an nEASY 1200 liquid chromatography system as described 
previously (16, 25). MS raw files were analyzed using the MaxQuant software to identify proteins and 
quantify their relative abundances (label free quantitation; LFQ) (26).
Transcriptomics. Five independent biological replicates for each condition were analyzed at all time 
points. A total of  100 ng cDNA libraries were prepared using the Illumina TruSeq mRNA Stranded Kit 
(Illumina) according to the manufacturer’s protocol. Libraries were sequenced using single-end reads (50 
nt–long) on an Illumina HiSeq4000. Library preparation and sequencing were performed at the iGE3 
Genomics Platform of  the University of  Geneva.
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High-dimensional FACS analysis. For T-distributed stochastic neighbor embedding (t-SNE) and Flow-
SOM, the exported FCS files were uploaded in Cy3 software (Matlab based), and Arcsinh cofactors were 
applied to every channel. Samples were then uploaded into Rstudio, and t-SNE and FlowSOM script were 
performed as described before (27).
Proteome analysis. Data analysis and quality control were performed using the Perseus software (28) and 
the R statistical computing environment. Quality control parameters included the number of  identified pro-
teins and correct expression of  the marker protein CD8. For statistical tests, missing values were imputed 
to simulate the distribution of  low signal values. The empirically defined parameters were: normal distribu-
tion of  30% of  the SD of  measured values and a 1.8 SD downshift of  the mean.
Transcriptome analysis. FastQ reads were mapped to the ENSEMBL reference genome (GRCm38.89) 
using STAR version 2.4.0j (29) with standard settings, except that any reads mapping to more than 1 
location in the genome (ambiguous reads) were discarded (m = 1). A unique gene model was used 
to quantify reads per gene, in which all annotated exons of  all annotated protein coding isoforms of  
a gene create a unique gene where the genomic regions of  all exons are considered coming from the 
same RNA molecule and merged together. All reads overlapping the exons of  each unique gene model 
were reported using featureCounts version 1.4.6-p1 (30). Gene expression was reported as raw counts 
and, in parallel, normalized as reads per kilobase of  transcript, per million mapped reads (RPKM) in 
order to filter out genes with low expression values (1 RPKM) before calling for differentially expressed 
genes. Library size normalizations and differential gene expression calculations were performed using 
the package edgeR (31) designed for the R software (32). Only genes having a significant fold change 
(Benjamini-Hochberg corrected P < 0.05) were considered for the rest of  the RNA-seq analysis. Gene 
Ontology (GO; http://geneontology.org) term and Kyoto Encyclopedia of  Genes and Genomes 
(KEGG; https://www.genome.jp/kegg/) metabolic pathway enrichment was performed using home-
made scripts for the R software (32).
For the GSEA, all annotated pathways for Mus musculus available on KEGG metabolic pathways 
database were used to generate gene sets, relative to GRCm38.89. Genes were ranked by their calculated 
fold-changes (decreasing ranking). A gene set analysis using the GSEA package Version 2.2 (33, 34) from 
the Broad Institute (MIT, Cambridge, Massachusetts, USA) was used to analyze the pattern of  differential 
gene expression between the 2 groups. Gene set permutations were performed 1000 times for each analysis. 
The normalized enrichment score (NES) was calculated for each gene set. GSEA results with a nominal 
FDR lower than 0.05 and an absolute NES bigger than 1 were considered significant.
Data and software availability. Sequence data has been submitted to the GEO database under the acces-
sion number GSE139811.
Statistics. Statistical parameters including the exact value of  n, the definition of  center, dispersion and 
precision measures, and statistical significance are indicated in the figures and figure legends. P values of  less 
than 0.05 were considered significant. Unless otherwise stated, bar plots and dot plots were judged using t 
tests. Normally distributed data were judged using 2-tailed unpaired Student’s t tests; nonnormally distributed 
data were judged using Mann-Whitney U tests. Tumor growth curves were judged using 2-way ANOVA. Sur-
vival analyses were judged using log-rank (Mantel-Cox) tests. Bonferroni correction was used when multiple 
comparisons were performed. Tumor-clearance rate analyses were judged using Fisher’s exact test. Differen-
tial gene expression was assessed by Wald test, using GLM in edgeR. Throughout the figures, asterisks denote 
statistical significance reported by the indicated statistic test (*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 
0.0001). Statistical analysis was performed in R or GraphPad PRISM software.
Study approval. Animal experimentation was reviewed and approved by the cantonal veterinary 
authority at the SCAV (Service de la consommation et des affaires vétérinaires) in Geneva, Switzer-
land, and performed according to Swiss animal protection laws. All blood donors at the Centre de 
Transfusion sanguine et don du sang of  the Universtiy Hospital of  Geneva provided and approved their 
informed consent to participate in the study.
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